Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

CYTOKINETICS INC (CYTK)

448 + Investors. Track Smart Money conviction in CYTK. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +47
Streak
2Q ▲
Buyers last Q
56%

Smart Money Signals — CYTK

Based on 411 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added CYTK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
411 hedge funds hold CYTK right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+84 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 56% buying

249 buying192 selling
Last quarter: 249 funds bought or added vs 192 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~100 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 58 → 29 → 99 → 100. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

51% of holders stayed for 2+ years

■ 51% conviction (2yr+) ■ 24% medium ■ 25% new
211 out of 411 hedge funds have held CYTK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Price up while funds trimmed (+14% value, -10% shares)

Value
+13%
Shares
-9%
Last quarter: total value of institutional CYTK holdings rose +14% even though funds reduced share count by 10%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
🚀

Acceleration phase — new buyers rushing in

42 → 58 → 29 → 99 → 100 new funds/Q
New funds entering each quarter: 58 → 29 → 99 → 100. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Deep conviction — 56% of holders stayed 2+ years

■ 56% veterans ■ 18% 1-2yr ■ 26% new
Of 448 current holders: 253 (56%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
🏆

Elite ownership — 55% AUM from top-100 funds

55% from top-100 AUM funds
44 of 411 holders are among the 100 largest funds by AUM, controlling 55% of total institutional value in CYTK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.0
out of 10
Moderate Exit Risk
Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CYTK

In 2025 Q4, 249 hedge funds were net buyers of CYTK (100 opened a new position, 149 added to an existing one), while 192 reduced or exited (139 trimmed, 53 sold completely) — a 56% buyer ratio, indicating a slight buying edge. Net buying has persisted for two consecutive quarters, a positive momentum signal. 55% of total institutional value in CYTK is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +47 funds (more new holders than closures). Total institutional holders: 411.

Hedge Fund Ownership: CYTK

How many hedge funds hold CYTK — quarterly history vs. share price
Quarterly hedge fund ownership of CYTK vs. share price

Market Analysis: CYTK

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CYTK

Healthcare Biotechnology

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

57 top-rated funds 15 high-conviction
Consensus
7.7
/ 10
breadth
×
Elite
4.6
/ 10
conviction
Hedge Fund Positioning: CYTK
2026 Q1 Stats Unlock in 9 days 448 + Investors

Track Smart Money conviction in CYTK. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change
Funds Holding 448 400 12.0%
13F Shares 138M 153M -9.63%
Total Value $9.01B $7.94B 13.53%
New Positions 103 101 +2
Increased Positions 200 162 +38
Closed Positions 56 34 +22
Reduced Positions 177 160 +17
Total Calls 25 29 -13.79%
Total Puts 19 14 35.71%
PUT/CALL Ratio 0.76 0.48 Neutral

Statistics: CYTK

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

448 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CYTK. Verified SEC 13F-HR filings.

Top 25 institutional holders of CYTK — 2025 Q4 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Royalty Pharma Sub-Manager, LLC 36.36% 980,392 $62.3M
2 ACT CAPITAL MANAGEMENT, LLC 3.34% 64,500 $4.3M
3 Mirador Capital Partners LP 1.89% 202,673 $13.4M
4 HARVEY CAPITAL MANAGEMENT INC 0.74% 49,295 $3.2M
5 E. Ohman J:or Asset Management AB 0.52% 300,762 $19.8M
6 MOODY ALDRICH PARTNERS LLC 0.44% 36,945 $2.4M
7 EMERALD MUTUAL FUND ADVISERS TRUST 0.43% 135,464 $8.9M
8 EMERALD ADVISERS, LLC 0.41% 198,811 $13.1M
9 PSP Research LLC 0.39% 8,300 $547K
10 AlphaCentric Advisors LLC 0.37% 5,616 $370K
11 Yorktown Management & Research Co Inc 0.26% 4,750 $313K
12 FNY Investment Advisers, LLC 0.26% 9,030 —
13 PEREGRINE CAPITAL MANAGEMENT LLC 0.25% 103,626 $6.8M
14 WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 0.24% 1,087,591 $71.7M
15 SANDERS MORRIS HARRIS LLC 0.22% 21,505 $1.4M
16 Veracity Capital LLC 0.17% 7,414 $489K
17 Ellsworth Advisors, LLC 0.16% 12,730 $839K
18 PINNACLE ASSOCIATES LTD 0.15% 177,062 $11.7M
19 NVWM, LLC 0.14% 9,217 $607K
20 F/m Investments LLC 0.13% 29,588 $2.0M
21 Candriam S.C.A. 0.11% 335,208 $22.1M
22 China Universal Asset Management Co., Ltd. 0.11% 21,856 $1.4M
23 Marks Group Wealth Management, Inc 0.11% 16,835 $1.1M
24 NJ State Employees Deferred Compensation Plan 0.09% 15,500 $852K
25 PROFUND ADVISORS LLC 0.09% 35,713 $2.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — CYTOKINETICS INC (CYTK)

What does the Smart Money Trend signal show for CYTK?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added CYTK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CYTK?

Slight buying edge — 56% buying: Last quarter: 249 funds bought or added vs 192 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CYTK holders?

Elite ownership — 55% AUM from top-100 funds: 44 of 411 holders are among the 100 largest funds by AUM, controlling 55% of total institutional value in CYTK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CYTK?

51% of holders stayed for 2+ years: 211 out of 411 hedge funds have held CYTK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.